TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer
Article in Molecular Oncology (April 2024)
The most recent citing publications are shown below. View all 166 publications that cite this research output on Dimensions.
Article in Molecular Oncology (April 2024)
Article in BMC Cancer (March 2024)
Book chapter (February 2024)